Introduction
============

For patients with a chronic prosthetic joint infection (PJI), removal of the infected prosthesis via a one- or two-stage revision surgery is required to cure the infection. The chance to cure the infection depends on multiple factors, including the affected joint, the microorganism(s) that are involved in the infection and several host-factors.[@B1]-[@B4] In general, if the infection is considered as difficult to treat, a two-stage surgical revision is indicated. Overall, the current success rates of revision surgery are quite high, on average, around 90% for both one-stage and two-stage procedures.[@B1]-[@B4]

Unfortunately, this means that in roughly 10% of patients, re-infection occurs and re-revision surgery is needed. Multiple revision surgeries ultimately diminish the chance to cure the infection due to poor bone stock and soft tissue injury.[@B5] As a result, complete removal of the prosthesis resulting in a Girdlestone situation, arthrodesis or lower-limb amputation is, in most cases, inevitable in order to eliminate the infection. Antibiotic suppressive therapy (AST) can be subscribed for these patients as alternative treatment to suppress the infection without removal of the prosthesis as long as possible, and to avoid these disabling surgeries. This conservative antibiotic treatment approach can also be applied in patients with a poor prognosis due to cancer, and in elderly patients or patients with severe comorbidity that are not vital enough to undergo revision surgery.

Apart from its main benefit, i.e. avoidance of complex and potentially harmful surgery, important disadvantages of AST may include treatment failure and unmanageable antibiotic side effects. Because of the ageing population and the subsequent rise of joint arthroplasties performed, it is expected that chronic PJI\'s and the number of \'inoperable patients\' increase.[@B6] Therefore, in the following decades, AST will probably play a more prominent role in the treatment of chronic PJI\'s. Patients, as well as treating orthopedic surgeons, infectiologists and medical microbiologists, should know of the advantages and disadvantages of AST. However, scientific data are scarce.

To determine the efficacy and tolerability of AST in patients who are treated with AST, we retrospectively evaluated our cohort of patients with a PJI who were treated according to this regime, in order to inform and guide physicians in making a balanced treatment decision for their patients.

Material and Methods
====================

Data collection
---------------

We retrospectively collected data from the period of January 2009 until January 2015 from patients with a chronic PJI that were treated with AST and followed at the University Medical Center Groningen. PJI was diagnosed using the diagnostic criteria described by the Infectious Diseases Society of America.[@B7] A chronic PJI was defined as symptoms that existed for more than 3 weeks. PJI was categorized in early (\< 3 month after implantation), delayed (3 months - 2 years after implantation) and late infection (\> 2 years after implantation). We collected the data by analyzing the reports of our weekly multidisciplinary meetings, where all patients with a PJI are discussed. Therefore, all subsequent patients in our center treated with AST are included in the study. AST was defined as antibiotic treatment that was started after the standard 3 months of \'regular\' antibiotic treatment (in most cases 2 weeks of intravenous therapy and 10 weeks of oral therapy). The choice for AST was based upon patients\' comorbidity, prognosis and the degree of tissue vitality and bone stock. The choice for AST was made by a multidisciplinary team consisting of orthopedic surgeons, infectiologists and medical microbiologists.

Besides demographic characteristics, we collected several patients\' parameters considered to be related to outcome; i.e. the patients\' underlying disease that led to joint arthroplasty, the affected joint, the number of revision surgeries that were performed in the affected joint prior to the start of AST, the type of prosthesis that was used (i.e. a standard or tumor prosthesis), the cultured micro-organisms that were accounted as the causative pathogens of the infection, the number of surgical debridements and lavages before suppression therapy was started and the indication reported for AST. We also evaluated the degree of inflammation by collecting the C-reactive protein (CRP), Erythrocyte Sedimentation Rate (ESR) and leucocytes in blood closest around the start of AST.

Outcome; definition of treatment failure
----------------------------------------

Treatment was considered as failed, when: 1) the patient still reported joint pain during follow-up visits at the outpatient clinic, 2) when surgical intervention was needed to control the infection (i.e. removal of the prosthesis (Girdlestone or arthrodesis), revision surgery and/or amputation/dysarticulation) and/or 3) when death occurred due to the infection.

Antibiotic treatment and side effects
-------------------------------------

The choice for the type of AST was based on the cultured micro-organism(s) and its susceptibility pattern(s), and the expected (long-term) side effects. The antibiotic treatment was advised by the involved medical microbiologist and/or infectiologist. If micro-organisms were considered as a contaminant and were not covered by the chosen antibiotic treatment, this was reported. Side effects of antibiotic treatment mentioned by patients during outpatient clinic visits were collected and noted whether these side effects led to dose adjustments, switch of therapy and/or discontinuation of treatment.

Follow-up
---------

Our patients visited the outpatient clinic at regular intervals (on average with a 3-6 month interval) to evaluate treatment response. When AST was successful for a longer time-period and patients experienced no side effects, some patients were followed by the general practitioner and were instructed to contact their treating orthopedic surgeon if problems arose. The time of follow-up was defined from the time point AST was started. The end-point of follow-up of our study was defined as: the patients\' last visit at our outpatient clinic and/or orthopedic ward during admission, or when treatment failed (as described above under: \'outcome; definition of treatment failure\').

Statistical analysis
--------------------

Since multiple variables may affect treatment outcome, we considered the number of included patients too small in order to perform a multiple regression analysis. Therefore, descriptive statistics were used to summarize the results. For continuous data (i.e. inflammatory parameters), the successful and failed treatment group were compared by using the Mann-Whitney U-test. All significance tests were performed 2-tailed. P-values \<0.05 were considered as statistically significant. Statistics was performed using Prism 7 for Mac OS X (1994-2016 GraphPad Software, Inc.).

Results
=======

Patient characteristics
-----------------------

In the period between January 2009 and January 2015, 24 patients in our center were started with oral AST. We excluded 3 patients from the analysis; 1 because of patient non-compliance (refused to take antibiotic therapy), 1 patient died from another cause than infection shortly after AST was started, and 1 patient was transferred to another hospital and was lost to follow-up. In total, 21 patients were included in the study. Table [1](#T1){ref-type="table"} shows the patients\' baseline characteristics and treatment outcome. The median age of the included patients was 67 years (range 21 - 88). A large proportion of our patients (45%) was obese (BMI ≥ 30), 54% were known with coronary heart disease, 14% with rheumatoid arthritis and 9% with diabetes mellitus. The majority of implants were revised prostheses (67%). PJI was caused by the following micro-organisms: *S. epidermidis* (n=6), *S. aureus* (n=6), polymicrobial flora (n=4), *P. acnes* (n=2), *S. agalactiae*(n=1), *S. pyogenes* (n=1) and *B. fragilis*(n=1). The median onset of PJI after implantation was 10 months (range 3-81 months). PJI was classified as an early infection in 24%, as a delayed infection in 33%, and as a late infection in 43% of patients. The indication to choose for AST was in 43% of patients because of poor bone stock and/or severe tissue injury. In most cases this was due to a malignancy or several revision surgeries in the past. 48% of patients were on AST because of a poor prognosis and/or severe comorbidity. In two cases, AST was because of patients\' refusal of surgery. 14 of the 21 patients (67%) underwent a debridement and/or lavage of the affected joint (mean number of procedures per patient: 1.5 (± 0.6 SD) before AST was started.

Treatment outcome and follow-up
-------------------------------

The median follow-up of patients was 21 months (range: 3-81). Overall, AST was successful in 67% of patients (Table [1](#T1){ref-type="table"}). Failure of treatment was due to persistent joint pain (n=1), surgical intervention because of an uncontrolled infection (n=3), and death due the infection (n=3). The number of debridement and/or lavage of the affected joint prior to the start of AST was approximately equal between the successful and failed treatment group (9 out of 14 patients (64%) versus 5 out of 7 patients (71%) respectively). Figure [1](#F1){ref-type="fig"} outlines the treatment outcome in association with several parameters. In general, we observed a treatment success of 90% in patients with a \'standard\' prosthesis (n=11). This success was only 50% in patients with a tumor-prosthesis (n=10). Also, treatment was successful in 83% of patients with a *S. epidermidis* as causative microorganism for the infection. For *S. aureus*, treatment success was only 50%. All patients with rheumatoid arthritis (n=3) failed on AST. All of these three patients were treated with methotrexate or prednisone. In our study, no difference in treatment outcome was observed between prosthetic knee and hip infections. Patients who failed on AST did not have a longer follow-up in comparison to patients whose treatment was successful (median follow up 15 months versus 27 months, respectively). Figure [2](#F2){ref-type="fig"} shows the treatment outcome in relation to inflammatory parameters. The median time point of laboratory values around the start (day 0) of AST, was +3 days (range -19 to -20 days). Patients who failed on AST had a higher ESR in comparison to patients with a successful treatment (mean 73 ± 25SD versus 32 ± 19SD mm/hour (p = 0.007), respectively).

Antibiotic suppressive therapy and reported side effects
--------------------------------------------------------

The \'regular\' antibiotic treatment, the type of AST, the reported side effects and whether these side effects led to a change in antibiotic treatment or dose adjustments, are shown in Table [2](#T2){ref-type="table"}. During the first chosen AST regime, nearly half of the patients reported side effects (43%), which led to a change in treatment in almost all of these patients, from which 50% was a dose adjustment and 50% a change in antibiotic treatment. On the second AST regime, only 3 out of 8 patients reported side effects. None of these 3 led to dose adjustments or a change in the antibiotic regime. Reported side effects were equal between the failed and successful treatment group. Overall, clindamycin was best tolerated; side effects were reported in only 2 out of 7 patients. Loss of appetite improved in one patient after the dose was adjusted to 300 mg TID. Minocycline was the least tolerated drug. Side effects were reported in 4 out of 6 patients, and led to a change of treatment or dose adjustment in all of these patients.

Discussion
==========

With a median follow-up of almost two years, we evaluated the efficacy and tolerability of AST in patients with a chronic PJI. With an overall treatment success of 67% - with the highest success rate observed in patients with a \'standard\' prosthesis and a *S. epidermidis* infection- our data showed that AST is a reasonable alternative treatment option for patients in whom revision surgery is not feasible or attractive because of a variety of reasons. Our treatment success is in agreement with previous studies, which report success rates between 63%-86%.[@B8]-[@B11] Reported success rates of \>80% in some studies can be explained by the inclusion of acute PJI\'s, from which it is known that retention of the prosthetic joint can be achieved.[@B7]

Based on our data, we cannot draw conclusions about prognostic factors for treatment success or failure. We did observe that treatment succeeded in almost all of our patients with a PJI caused by a *S. epidermidis.*This finding may not sound surprising since *S. epidermidis* has low virulence and its natural course of infection is often smouldering and low-grade in nature. However, Barberan et al. did show a 50% relapse rate in patients with a PJI caused by coagulase negative staphylococci (CNS) and who were treated with a conservative treatment regime (i.e. surgical debridement with implant retention and a 3 month course of antibiotic treatment). In addition, Byren et al. showed that when antibiotic treatment is discontinued, even after a long period of suppression therapy (with a minimum of 180 days), relapse of infection occurs in around 30% of patients.[@B12] Therefore, long-term antibiotic treatment in patients with a PJI due CNS does have additional value to suppress the infection, and its favorable outcome is not merely due to its natural course. We also observed a high success rate in patients with a \'standard\' prosthesis, in comparison with patients with a \'tumor\' prosthesis, in whom 50% of AST failed. In previous studies on AST, the type of prosthesis is not mentioned. However, it is known, that tumor prostheses are more prone to infection in comparison to standard prostheses. This may be partly explained by poor soft tissue and/or bone stock due to radiation therapy, and the larger surface area of a \'tumor\' prosthesis.[@B13] In contrast to other studies, in our cohort of patients, we did not observe higher failure rates in patients with multiple prior revision surgeries or in patients with knee arthroplasties.[@B8]

To our knowledge, we are the first who evaluated the degree of inflammation in relation to treatment outcome. Although laboratory data were not available for every patient shortly before or after the start of AST, we believe our results do suggest that patients who have an ESR \> 65 mm/h when suppression therapy is started, probably have a higher chance of treatment failure. Our three patients with rheumatoid arthritis all failed on AST, two of them had an ESR \> 65 mm/h. In previous studies, rheumatoid arthritis and/or the use of immunosuppressive medication has not been evaluated as variable for treatment outcome, and would be interesting to include as potential prognostic factor in future studies.

Our data give a good impression about the challenges patients and treating physicians face regarding potential side effects of AST. 43% our patients experienced side effect during antibiotic therapy. Although the majority of them needed a switch of therapy or an alternation of dose, the antibiotic treatment was ultimately well tolerated. The number of side effects whilst on the \'first\' antibiotic regime is in accordance with the study of Tsukayama et al.[@B14] They also report side effects in 38% of patients that led to a change in antibiotic therapy. In our study, no severe side effects occurred. One previous study reported a 22% incidence (4 out of 18 patients) of *Clostridum difficile* infection.[@B15] This high incidence might be due to the longer follow-up of this study (at least 4 years) or due to the use of a different antibiotic treatment regime in the 4 patients with a Clostridium infection (2 patients were treated with with dicloxacillin).[@B16]-[@B17]

In conclusion, for patients with a PJI who are no candidate for revision surgery antibiotic suppressive therapy seems a reasonable alternative treatment, with the highest success rates in patients with a standard-prosthesis or with a *S. epidermidis* infection. Although side effects occur frequently, most patients finally tolerate treatment after a change in therapy has been made. Although numbers are low, antibiotic suppressive therapy failed for all our patients with rheumatoid arthritis.
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![Outcome of antibiotic suppressive therapy (n=21) subdivided in several parameters; the affected joint (A), the indication for the prosthesis / underlying condition (B), the type of prosthesis (C) and the causative pathogen / micro-organism for the prosthetic joint infection (PJI) (D). The definition of successful treatment and failed treatment is descripted in the text.](jbjiv02p0077g001){#F1}

![Outcome of antibiotic suppressive therapy (n=21) in relation to inflammatory parameters before suppression therapy was started); C-reactive protein (CRP) (A), Estimated Sedimentation Rate (ESR) (B), and leucocytes (C). The definition of successful treatment and failed treatment is descripted in the text. Bars represent the median, the 25^th^ and the 75^th^ percentile.](jbjiv02p0077g002){#F2}

###### 

Overview of patient characteristics and outcome of antibiotic suppressive therapy (AST).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pt   Sex   Age   Indication AST                Indication\      Revised\     Affected\   Type of\     Months after\   Surgeries before\      Micro-\                          Outcome      
                                                 prosthesis       prosthesis   joint       prosthesis   implantation    start AST (n)          organism(s)                                   
  ---- ----- ----- ----------------------------- ---------------- ------------ ----------- ------------ --------------- ---------------------- -------------------------------- ------------ --
  1    M     70    comorbidity                   osteoarthritis   yes          hip         standard     54 (late)       lavage (3)             *S. pyogenes*                    Successful   

  2    M     69    comorbidity/prognosis         malignancy       yes          hip         tumor        1 (early)       no                     *S. epidermidis*                 Successful   

  3    M     40    poor soft tissue              malignancy       yes          hip         tumor        1 (early)       lavage (1)             *S. aureus*                      Successful   

  4    M     71    prognosis                     malignancy       yes          hip         standard     1 (early)       no                     *S. epidermidis, E.cloacae*      Successful   

  5    F     76    comorbidity                   osteoarthritis   yes          knee        standard     30 (late)       no                     *S. epidermidis*                 Successful   

  6    F     55    comorbidity/prognosis         malignancy       yes          hip         standard     1 (early)       lavage (1)             *S. aureus, E. faecalis*         Successful   

  7    F     71    patient wish                  osteoarthritis   yes          hip         standard     39 (late)       lavage (1)             *Bacteroides fragilis*           Successful   

  8    F     47    poor soft tissue/bone stock   osteoarthritis   yes          hip         standard     1 (early)       DAIR (1), lavage (1)   *S. epidermidis (rifampin R)*    Successful   

  9    M     80    comorbidity                   fracture         no           shoulder    standard     1 (early)       lavage (1)             *P. acnes*                       Successful   

  10   M     52    pore bonestock/prognosis      malignancy       no           knee        tumor        6 (delayed)     DAIR (1)               *S. aureus*                      Successful   

  11   M     35    pore bonestock                osteomyelitis    yes          hip         tumor        44 (late)       no                     *S. epidermidis*                 Successful   

  12   M     21    prognosis                     malignancy       no           knee        tumor        24 (late)       excision sarcoma       *P. acnes*                       Successful   

  13   M     73    poor soft tissue/bone stock   fracture         yes          hip         standard     78 (late)       DAIR (1), lavage (2)   *S. aureus*                      Successful   

  14   M     88    comorbidity/prognosis         osteoarthritis   no           knee        standard     1 (early)       lavage (2)             *S. epidermidis*                 Successful   

  15   F     54    poor bonestock                RA               yes          knee        tumor        27 (late)       no                     *S. aureus*                      Failed ^1^   

  16   M     70    comorbidity/prognosis         RA               yes          knee        standard     176 (late)      lavage (1)             *S. aureus*                      Failed ^2^   

  17   F     59    poor soft tissue/bone stock   osteoarthritis   yes          hip         tumor        6 (delayed)     resposition (3)        *S. aureus, S. epidermidis*      Failed ^1^   

  18   F     67    poor soft tissue              fracture         no           shoulder    standard     7 (delayed)     lavage (2)             *S. aureus*                      Failed ^2^   

  19   M     58    patient wish                  malignancy       no           hip         tumor        2 (early)       DAIR (2)               *E.coli*(ESBL+)*, E. faecalis*   Failed ^2^   

  20   M     68    poor soft tissue              fracture         no           hip         tumor        43 (late)       DAIR (1), lavage (2)   *S. agalactiae*                  Failed ^3^   

  21   F     65    comorbidity                   RA               yes          hip         tumor        9 (delayed)     DAIR (1)               *S. epidermidis*                 Failed ^1^   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DAIR: debridement, antibiotics, irrigation and retention.

Definition of failed outcome: ^1^ surgical intervention needed, ^2^ death due to persistent prosthetic joint infection, ^3^ persistent pain. RA: rheumatoid arthritis.

###### 

Overview of the initial treatment and the antibiotic suppressive therapy (AST) per patient, the reported side effects and subsequent intervention.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pt   Intravenous\                    Oral treatment^2^             1^st^ AST                   Side effects\           Change of\   2^nd^ AST                  Side effects AST   Change of\
       treatment^1^                                                                              AST                     treatment                                                  treatment
  ---- ------------------------------- ----------------------------- --------------------------- ----------------------- ------------ -------------------------- ------------------ ------------
  1    Penicillin 12 mU /day           Amoxicillin 1000 mg TID       Amoxicillin 500 mg TID      No                      \-           \-                         \-                 \-

  2    Vancomycin/day^3^, 4w           Minocycline 100 mg BID        Minocycline 100 mg BID      Nausea, phototoxicity   Yes          Minocycline 100 mg QD      Phototoxicity      No

  3    Penicillin 12 mU/day            Moxifloxacin 400 mg QD\       Moxifloxacin 400 mg QD      No                      \-           \-                         \-                 \-
                                       Rifampin^4^ 450 mg BID                                                                                                                       

  4    Vancomycin/day^3^\              Ciprofloxacin 750 mg BID\     Minocycline 100 mg BID      Nausea, vomiting        Yes          Doxycyclin 100 mg QD       No                 \-
       Ciprofloxacin 400 mg TID        Rifampin^4^ 450 mg BID\                                                                                                                      
                                       Linezolid 600 mg BID, 4w\                                                                                                                    
                                       Mincocyline 100 mg BID, 6w                                                                                                                   

  5    \-                              \-                            Moxifloxacin 400 mg QD      Nausea                  No           \-                         \-                 \-

  6    Amoxicillin 12 g/day\           Amox/clav 500/125 QID\        Amox/clav 500/125 mg TID    No                      \-           \-                         \-                 \-
       Flucloxacillin 12 g/day\        Rifampin^4^ 450 mg BID                                                                                                                       
       Gentamicin 3 mg/kg/day                                                                                                                                                       

  7    \-\                             Metronidazole 500 mg QID\     Amox/clav 500/125 mg TID    Nausea                  Yes          Minocycline 100 mg QD      Dizziness          No
       -                               Amox/clav 750/125 TID                                                                                                                        

  8    Vancomycin/day^3^               Mincocyline 100 mg BID        Minocycline 100 mg QD       No                      \-           \-                         \-                 \-

  9    Ceftriaxone 2 g QD              Clindamycin 600 mg TID\       Amoxicillin 500 mg TID      Dry mouth               Yes          Amoxicillin 375 mg TID     Malaise            No
                                       Rifampin^4^ 450 mg BID                                                                                                                       

  10   Flucloxacillin 12 g/day         Moxifloxacin 400 mg QD\       Clindamycin 450 mg TID      No                      \-           \-                         \-                 \-
                                       Rifampin^4^ 450 mg BID                                                                                                                       

  11   \-                              Linezolid 600 mg BID, 4w\     Minocycline 100 mg BID      Diarrhea                Yes          Minocycline 100 mg QD      No                 \-
                                       Mincocyline 100 mg BID, 8w                                                                                                                   

  12   Flucloxacillin 12 g/day         Moxifloxacin 400 mg QD\       Clindamycin 450 mg TID      Nausea                  Yes          Moxifloxacin 400 mg QD     No                 \-
                                       Rifampin^4^ 450 mg BID                                                                                                                       

  13   Flucloxacillin 12 g/day         Moxifloxacin 400 mg QD\       Clindamycin 600 mg TID      No                      \-           \-                         \-                 \-
                                       Rifampin^4^ 450 mg BID                                                                                                                       

  14   Vancomycin/day^3^               Linezolid 600 mg BID, 4w\     Minocycline 100 mg QD       No                      \-           \-                         \-                 \-
                                       Mincocyline 100 mg BID, 6w                                                                                                                   

  15   \-                              Clindamycin 600 mg TID        Clindamycin 600 mg TID      Loss of appetite        Yes          Clindamycin 300 mg TID     No                 \-

  16   Flucloxacillin 8 g^5^/day, 1w   Clindamycin 600 mg TID        Clindamycin 600 mg TID      No                      \-           \-                         \-                 \-

  17   Daptomycin 8 mg/kg/day^6^       Mincocyline 100 mg BID\       Minocycline 100 mg BID      Skin rash               Yes          Cotrimoxazole 960 mg BID   No                 \-
                                       Rifampin^4^ 450 mg BID                                                                                                                       

  18   Flucloxacillin 8 g/day^5^       Moxifloxacin 400 mg QD\       Clindamycin 600 mg TID      No                      \-           \-                         \-                 \-
                                       Rifampin^4^ 450 mg BID                                                                                                                       

  19   Meropenem 2 g TID\              Ciprofloxacin 750 mg BID\     Cotrimoxazole 960 mg BID\   No\                     \-\          \-\                        \-\                \-\
       Vancomycin/day^3^\              Amoxicillin 1000 mg TID       Amoxicillin 1000 mg TID     No                      -            -                          -                  -
       Gentamicin 3 mg/kg/day                                                                                                                                                       

  20   Penicillin 12 mU/day, 4w\       Amoxicillin 1000 mg TID, 8w   Amoxicillin 500 mg TID      No                      \-           \-                         \-                 \-
       Gentamicin 3 mg/kg/day, 4w                                                                                                                                                   

  21   \-                              \-                            Clindamycin 450 mg TID      No                      \-           \-                         \-                 \-
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Intravenous treatment comprises 2 weeks of treatment, unless otherwise stated. ^2^ Oral treatment comprises 10 weeks of treatment, unless otherwise stated. ^3^ The dose of vancomycin was determined by therapeutic drug monitoring, aiming towards a serum concentration level of ±25 mg/L (continuous infusion). ^4^ In general, rifampin is added during intravenous treatment after susceptibility is known (after ± 5 days). ^5^ 8 grams of flucloxacillin was chosen because of renal insufficiency. ^6^ Daptomycin was chosen because of allergy to penicillin.
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